Recurrent or refractory glypican 3 (GPC3)

Clinical trials for Recurrent or refractory glypican 3 (GPC3) explained in plain language.

Never miss a new study

Get alerted when new Recurrent or refractory glypican 3 (GPC3) trials appear

Sign up with your email to follow new studies for Recurrent or refractory glypican 3 (GPC3), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Experimental antibody targets childhood cancers in first human trial

Disease control Recruiting now

This early-stage study tests a drug called codrituzumab in children and young adults (ages 1 to 21) whose solid tumors have come back or not responded to treatment and carry a specific protein called GPC3. The main goal is to find a safe dose and see how the body handles the drug…

Matched conditions: RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3)

Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Sep 03, 2026 00:00 UTC

Recurrent or refractory glypican 3 (GPC3)

Get alerted when new Recurrent or refractory glypican 3 (GPC3) trials appear

Experimental antibody targets childhood cancers in first human trial